Among the findings, Cerulean will present clinical and pre-clinical efficacy data for CRLX101 as a combination therapy with anti-angiogenic therapies for renal cell carcinoma and ovarian cancer.
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/Phase+News/Cerulean-Presentation-Selected-as-a-Top-Poster-at-/ArticleNewsFeed/Article/detail/825920?ref=25
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/Phase+News/Cerulean-Presentation-Selected-as-a-Top-Poster-at-/ArticleNewsFeed/Article/detail/825920?ref=25
No comments:
Post a Comment